Last reviewed · How we verify
NCT07484971: CLIQQC
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
trial in Prostate Cancer in 2,000 participants. Currently enrolling.
21 July 2026
Quick facts
| Lead sponsor | Société Algérienne de Formation et Recherche en Oncologie |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 21 July 2025 |
| Primary completion | 21 July 2026 |
| Estimated completion | 21 July 2026 |
| Sites | 24 locations across Algeria |
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Prostate Cancer (Diagnosis) — all drugs for Prostate Cancer (Diagnosis) →
- Prostate Cancer (Post Prostatectomy) — all drugs for Prostate Cancer (Post Prostatectomy) →
- Prostate Cancer Patients Treated by Radiotherapy — all drugs for Prostate Cancer Patients Treated by Radiotherapy →
Sponsor
Société Algérienne de Formation et Recherche en Oncologie
Who can join
19 and older, male only, with Prostate Cancer or Prostate Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07484971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
Other Société Algérienne de Formation et Recherche en Oncologie trials
Trials by the same sponsor.
- NCT07481110 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07484971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Société Algérienne de Formation et Recherche en Oncologie
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07484971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing